Patents by Inventor Shiri Ashkenazi

Shiri Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GUT MICROBIOTA AND TREATMENT OF CANCER
    Publication number: 20230270795
    Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
    Type: Application
    Filed: January 30, 2023
    Publication date: August 31, 2023
    Inventors: Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze`ev Ronai, Shiri Ashkenazi
  • Gut microbiota and treatment of cancer
    Patent number: 11571446
    Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 7, 2023
    Assignees: Sanford Bumham Prebys Medical Discovery Institute, Technion Research & Development Foundation Ltd.
    Inventors: Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze'ev Ronai, Shiri Ashkenazi
  • GUT MICROBIOTA AND TREATMENT OF CANCER
    Publication number: 20190365829
    Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Inventors: Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze`ev Ronai, Shiri Ashkenazi